JP2011508875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011508875A5 JP2011508875A5 JP2010538902A JP2010538902A JP2011508875A5 JP 2011508875 A5 JP2011508875 A5 JP 2011508875A5 JP 2010538902 A JP2010538902 A JP 2010538902A JP 2010538902 A JP2010538902 A JP 2010538902A JP 2011508875 A5 JP2011508875 A5 JP 2011508875A5
- Authority
- JP
- Japan
- Prior art keywords
- gpcr
- variant
- parent
- leu
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 138
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 138
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 45
- 238000000034 method Methods 0.000 claims 38
- 239000003446 ligand Substances 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 29
- 102000005962 receptors Human genes 0.000 claims 16
- 108020003175 receptors Proteins 0.000 claims 16
- 102000017922 Neurotensin receptor Human genes 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 9
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 9
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 8
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 150000002632 lipids Chemical class 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 7
- -1 column Substances 0.000 claims 7
- 102000018697 Membrane Proteins Human genes 0.000 claims 6
- 108010052285 Membrane Proteins Proteins 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 102000009346 Adenosine receptors Human genes 0.000 claims 5
- 108050000203 Adenosine receptors Proteins 0.000 claims 5
- 108060003370 Neurotensin receptor Proteins 0.000 claims 5
- 101500028886 Rattus norvegicus Neurotensin Proteins 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 4
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 229960005305 adenosine Drugs 0.000 claims 4
- 239000011324 bead Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- GJLXVWOMRRWCIB-MERZOTPQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=C(O)C=C1 GJLXVWOMRRWCIB-MERZOTPQSA-N 0.000 claims 3
- 102000016359 Fibronectins Human genes 0.000 claims 3
- 108010067306 Fibronectins Proteins 0.000 claims 3
- 239000000232 Lipid Bilayer Substances 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000010410 layer Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 102000016904 Armadillo Domain Proteins Human genes 0.000 claims 2
- 108091006027 G proteins Proteins 0.000 claims 2
- 102000030782 GTP binding Human genes 0.000 claims 2
- 108091000058 GTP-Binding Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 claims 2
- 108090000848 Ubiquitin Proteins 0.000 claims 2
- 102000044159 Ubiquitin Human genes 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 230000003196 chaotropic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000036425 denaturation Effects 0.000 claims 2
- 238000004925 denaturation Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000013069 gamma-Crystallins Human genes 0.000 claims 2
- 108010079934 gamma-Crystallins Proteins 0.000 claims 2
- 239000011521 glass Substances 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 239000013554 lipid monolayer Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229930014626 natural product Natural products 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000003725 proteoliposome Substances 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- BXOCHUWSGYYSFW-HVWOQQCMSA-N spilanthol Chemical group C\C=C\C=C/CC\C=C\C(=O)NCC(C)C BXOCHUWSGYYSFW-HVWOQQCMSA-N 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 239000013076 target substance Substances 0.000 claims 2
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- 102000008102 Ankyrins Human genes 0.000 claims 1
- 108010049777 Ankyrins Proteins 0.000 claims 1
- 102000003916 Arrestin Human genes 0.000 claims 1
- 108090000328 Arrestin Proteins 0.000 claims 1
- 108090001008 Avidin Proteins 0.000 claims 1
- 101001086405 Bos taurus Rhodopsin Proteins 0.000 claims 1
- 101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 238000004435 EPR spectroscopy Methods 0.000 claims 1
- 102000008924 GPCR kinases Human genes 0.000 claims 1
- 108050000878 GPCR kinases Proteins 0.000 claims 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims 1
- 108091006109 GTPases Proteins 0.000 claims 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 claims 1
- 101000596394 Homo sapiens Vesicle-fusing ATPase Proteins 0.000 claims 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- 108010067902 Peptide Library Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000008944 RGS Proteins Human genes 0.000 claims 1
- 108010074020 RGS Proteins Proteins 0.000 claims 1
- 238000001069 Raman spectroscopy Methods 0.000 claims 1
- 108700008625 Reporter Genes Proteins 0.000 claims 1
- 108010073443 Ribi adjuvant Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 1
- 102100035054 Vesicle-fusing ATPase Human genes 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 102000000072 beta-Arrestins Human genes 0.000 claims 1
- 108010080367 beta-Arrestins Proteins 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 230000008034 disappearance Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002359 drug metabolite Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000005669 field effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 claims 1
- 238000002875 fluorescence polarization Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000005484 gravity Effects 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 102000055647 human CSF2RB Human genes 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- 238000004020 luminiscence type Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 239000010453 quartz Substances 0.000 claims 1
- 238000010791 quenching Methods 0.000 claims 1
- 230000000171 quenching effect Effects 0.000 claims 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0724860.2A GB0724860D0 (en) | 2007-12-20 | 2007-12-20 | Screening |
| GB0724860.2 | 2007-12-20 | ||
| PCT/GB2008/004223 WO2009081136A2 (en) | 2007-12-20 | 2008-12-19 | Screening |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117562A Division JP6425620B2 (ja) | 2007-12-20 | 2015-06-10 | スクリーニング |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011508875A JP2011508875A (ja) | 2011-03-17 |
| JP2011508875A5 true JP2011508875A5 (enExample) | 2012-09-13 |
| JP5763343B2 JP5763343B2 (ja) | 2015-08-12 |
Family
ID=39048448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538902A Active JP5763343B2 (ja) | 2007-12-20 | 2008-12-19 | スクリーニング |
| JP2015117562A Active JP6425620B2 (ja) | 2007-12-20 | 2015-06-10 | スクリーニング |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117562A Active JP6425620B2 (ja) | 2007-12-20 | 2015-06-10 | スクリーニング |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US8790933B2 (enExample) |
| EP (2) | EP2573563B1 (enExample) |
| JP (2) | JP5763343B2 (enExample) |
| AU (1) | AU2008339595C1 (enExample) |
| CA (1) | CA2710145C (enExample) |
| ES (1) | ES3006458T3 (enExample) |
| GB (2) | GB0724860D0 (enExample) |
| WO (1) | WO2009081136A2 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2121919B1 (en) | 2007-03-22 | 2012-02-08 | Heptares Therapeutics Limited | Mutant g-protein coupled receptors and methods for selecting them |
| GB0724051D0 (en) * | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| GB0802474D0 (en) * | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| WO2008068534A2 (en) * | 2008-03-05 | 2008-06-12 | Heptares Therapeutics Limited | Crystal structure of a betal -adremergi c receptor and uses thereof |
| GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| US9772272B2 (en) | 2009-09-28 | 2017-09-26 | Koninklijke Philips N.V. | Substance determining apparatus |
| GB201014715D0 (en) * | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| EP3333185A1 (en) | 2010-08-20 | 2018-06-13 | Heptares Therapeutics Limited | Mutant gpcrs |
| WO2011033322A2 (en) * | 2011-01-07 | 2011-03-24 | Heptares Therapeutics Ltd | Crystal structure |
| JP6263773B2 (ja) | 2011-02-23 | 2018-01-24 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質およびその調製および使用方法 |
| WO2012120315A2 (en) * | 2011-03-10 | 2012-09-13 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
| DK2742066T3 (en) | 2011-08-10 | 2018-03-05 | Heptares Therapeutics Ltd | STABLE PROTEINS |
| EP2578695A1 (en) * | 2011-10-05 | 2013-04-10 | Albert-Ludwigs-Universität Freiburg | Assay for Clostridium botulinum Neurotoxin |
| JP6251252B2 (ja) | 2012-06-01 | 2017-12-20 | ヘプタレス セラピューティックス リミテッド | アッセイ |
| WO2014045081A1 (en) * | 2012-09-18 | 2014-03-27 | Adocia | Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein |
| US20150216977A1 (en) | 2012-09-18 | 2015-08-06 | Adocia | Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein |
| PT2951201T (pt) | 2013-01-30 | 2018-01-09 | Univ Brussel Vrije | Novos polipéptidos quiméricos para rastreamento e fins de descoberta de fármacos |
| WO2014124020A1 (en) | 2013-02-05 | 2014-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner |
| ES2900571T3 (es) * | 2013-06-11 | 2022-03-17 | Scherrer Inst Paul | Método para determinar la unión de un ligando-GPCR mutante a resolución de un único aminoácido y parejas de ligando mutado y GPCR |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| GB201415094D0 (en) | 2014-08-26 | 2014-10-08 | Heptares Therapeutics Ltd | GPCR receptor binding domain and uses thereof |
| US20170316147A1 (en) | 2014-10-27 | 2017-11-02 | King Abdullah University Of Science And Technology | Methods and systems for identifying ligand-protein binding sites |
| WO2016070022A1 (en) | 2014-10-31 | 2016-05-06 | Abilita Bio, Inc. | Modified membrane spanning proteins and methods for the preparation and use thereof |
| WO2017027523A1 (en) * | 2015-08-10 | 2017-02-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Stabilized vesicle-functionalized microparticles for chemical separations and polymer frits in silica capillaries using spatially-defined thermal polymerization |
| GB201601690D0 (en) | 2016-01-29 | 2016-03-16 | Heptares Therapeutics Ltd | G proteins |
| AU2017259821B2 (en) | 2016-05-04 | 2024-07-18 | Abilita Bio, Inc. | Methods and platform for preparing multispanning membrane proteins |
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| US10320280B2 (en) * | 2016-11-08 | 2019-06-11 | Analog Devices Global Unlimited Company | LC filter including coupled inductors for reducing ripple in switching power supplies |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| WO2019006436A1 (en) | 2017-06-30 | 2019-01-03 | Inscripta, Inc. | METHODS, MODULES, INSTRUMENTS AND SYSTEMS FOR AUTOMATED CELL PROCESSING |
| FR3069644B1 (fr) * | 2017-07-28 | 2024-07-12 | Cisbio Bioassays | Methode pour mesurer la modulation de l'activation d'un recepteur couple a une proteine g |
| MX2020004561A (es) * | 2017-11-02 | 2020-08-13 | Bayer Ag | Anticuerpos biespecificos que se unen a alk-1 y bmpr-2. |
| WO2019200004A1 (en) | 2018-04-13 | 2019-10-17 | Inscripta, Inc. | Automated cell processing instruments comprising reagent cartridges |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| WO2019209926A1 (en) * | 2018-04-24 | 2019-10-31 | Inscripta, Inc. | Automated instrumentation for production of peptide libraries |
| US10557216B2 (en) | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
| US11262309B2 (en) * | 2018-07-11 | 2022-03-01 | Advanced Cytometry Instrumentation Systems, Llc | Methods for lipid measurement in cells |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| US10532324B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US10533152B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| EA202092684A1 (ru) | 2018-08-27 | 2021-03-11 | Ридженерон Фармасьютикалз, Инк. | Применение рамановской спектроскопии для последующей очистки |
| AU2019363487A1 (en) | 2018-08-30 | 2021-04-15 | Inscripta, Inc. | Improved detection of nuclease edited sequences in automated modules and instruments |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| WO2020086475A1 (en) | 2018-10-22 | 2020-04-30 | Inscripta, Inc. | Engineered enzymes |
| JP7216216B2 (ja) * | 2019-01-22 | 2023-01-31 | インターアクス バイオテック アー・ゲー | ベータ－アレスチン突然変異体 |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| EP3947691A4 (en) | 2019-03-25 | 2022-12-14 | Inscripta, Inc. | SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST |
| US12360107B2 (en) | 2019-05-31 | 2025-07-15 | Arizona Board Of Regents On Behalf Of The Univeristy Of Arizona | Synthesis of nanoSCINT particles |
| US10837021B1 (en) | 2019-06-06 | 2020-11-17 | Inscripta, Inc. | Curing for recursive nucleic acid-guided cell editing |
| EP3986909A4 (en) | 2019-06-21 | 2023-08-02 | Inscripta, Inc. | Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli |
| US10927385B2 (en) | 2019-06-25 | 2021-02-23 | Inscripta, Inc. | Increased nucleic-acid guided cell editing in yeast |
| CA3155601A1 (en) * | 2019-10-01 | 2021-04-08 | Ac Immune Sa | Micro-radiobinding assays for ligand screening |
| US11203762B2 (en) | 2019-11-19 | 2021-12-21 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| KR20250033331A (ko) | 2019-12-10 | 2025-03-07 | 인스크립타 인코포레이티드 | 신규 mad 뉴클레아제 |
| US10704033B1 (en) | 2019-12-13 | 2020-07-07 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| EP4069851A4 (en) | 2019-12-18 | 2023-11-22 | Inscripta, Inc. | Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
| US10689669B1 (en) | 2020-01-11 | 2020-06-23 | Inscripta, Inc. | Automated multi-module cell processing methods, instruments, and systems |
| KR20220133257A (ko) | 2020-01-27 | 2022-10-04 | 인스크립타 인코포레이티드 | 전기천공 모듈 및 기구 |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
| US11299731B1 (en) | 2020-09-15 | 2022-04-12 | Inscripta, Inc. | CRISPR editing to embed nucleic acid landing pads into genomes of live cells |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| WO2022146497A1 (en) | 2021-01-04 | 2022-07-07 | Inscripta, Inc. | Mad nucleases |
| WO2022150269A1 (en) | 2021-01-07 | 2022-07-14 | Inscripta, Inc. | Mad nucleases |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
| CN114836517A (zh) * | 2022-04-20 | 2022-08-02 | 合肥中科普瑞昇生物医药科技有限公司 | 一种A2aR拮抗剂的高通量筛选体系及其应用 |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| WO2024206508A2 (en) * | 2023-03-28 | 2024-10-03 | Ibrahim Yasir H | Methods of enzyme purification using g-proteins as controllable affinity probes |
| EP4621788A1 (en) * | 2024-03-22 | 2025-09-24 | Genome Research Limited | Gpcr |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68929151T2 (de) | 1988-10-28 | 2000-07-20 | Genentech, Inc. | Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten |
| US6780613B1 (en) * | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| JP3147916B2 (ja) | 1991-03-08 | 2001-03-19 | 森永製菓株式会社 | 体外免疫方法 |
| EP1471142B1 (en) | 1991-04-10 | 2008-11-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US20030036092A1 (en) * | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| US5585277A (en) * | 1993-06-21 | 1996-12-17 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
| WO1995032425A1 (en) | 1994-05-23 | 1995-11-30 | Smithkline Beecham Corporation | Encoded combinatorial libraries |
| US20020028443A1 (en) * | 1999-09-27 | 2002-03-07 | Jay M. Short | Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process |
| AU2020497A (en) | 1996-03-27 | 1997-10-17 | Susan R. George | Receptor and transporter antagonists |
| WO1997039131A1 (en) * | 1996-04-15 | 1997-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Soluble 7-transmembrane domain g-protein-coupled receptor compositions and methods |
| US6153410A (en) * | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| US6541209B1 (en) * | 1997-04-14 | 2003-04-01 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| WO1999051773A1 (en) * | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| US6475733B1 (en) * | 1998-04-06 | 2002-11-05 | Lerner Pharmaceuticals, Inc. | Cell surface receptors for the detection and identification of compounds |
| US6692696B1 (en) * | 1998-06-18 | 2004-02-17 | ARETé ASSOCIATES | Biosensor |
| US7094593B1 (en) * | 1998-09-01 | 2006-08-22 | Basf Aktiengesellschaft | Method for improving the function of heterologous G protein-coupled receptors |
| WO2000070343A2 (en) * | 1999-05-14 | 2000-11-23 | Repliscent, Inc. | G-protein coupled receptor based biosensors and sense replication systems |
| NZ531722A (en) | 1999-11-17 | 2006-06-30 | Arena Pharm Inc | Endogenous and non-endogenous versions of human G protein-coupled receptors |
| MXPA02007730A (es) * | 2000-02-09 | 2002-10-11 | Human Genome Sciences Inc | Receptor de quimiocina de proteina g humana (ccr5) hdgnr10. |
| WO2001070765A1 (en) * | 2000-03-21 | 2001-09-27 | Consensus Pharmaceuticals, Inc. | Receptor-binding compounds and methods for identifying them |
| MXPA02009902A (es) * | 2000-04-07 | 2003-06-17 | Arena Pharm Inc | Receptores acoplados a proteina g, conocidos, activados constitutivamente, no endogenos. |
| US7678539B2 (en) * | 2000-08-10 | 2010-03-16 | Corning Incorporated | Arrays of biological membranes and methods and use thereof |
| US7462457B2 (en) * | 2000-08-30 | 2008-12-09 | Johns Hopkins University School Of Medicine | Identification of activated receptors and ion channels |
| US6448377B1 (en) * | 2000-09-27 | 2002-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Modified G protein sunbunits |
| EP1353555A2 (en) | 2000-10-26 | 2003-10-22 | New England Medical Center Hospitals, Inc. | Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents |
| US20030232331A1 (en) | 2000-12-05 | 2003-12-18 | Casman Stacie J. | Novel proteins and nucleic acids encoding same |
| WO2002083736A2 (en) | 2001-02-14 | 2002-10-24 | Amgen, Inc. | G-protein coupled receptor molecules and uses thereof |
| CN1516706A (zh) | 2001-02-26 | 2004-07-28 | 阿伦纳药品公司 | 人g蛋白偶联受体的内源性和非内源性形式 |
| US7208279B2 (en) * | 2001-03-14 | 2007-04-24 | Caden Biosciences, Inc. | Method for identifying inhibitors of G protein coupled receptor signaling |
| US7294472B2 (en) | 2001-03-14 | 2007-11-13 | Caden Biosciences | Method for identifying modulators of G protein coupled receptor signaling |
| US20070010948A1 (en) | 2001-03-30 | 2007-01-11 | Masaji Ishiguro | G protein-coupled receptor structural model and a method of designing ligand binding to g protein-coupled receptor by using the structural model |
| US20030129649A1 (en) * | 2001-04-24 | 2003-07-10 | Kobilka Brian K. | Conformational assays to detect binding to G protein-coupled receptors |
| US20050009204A1 (en) * | 2003-07-11 | 2005-01-13 | Ye Fang | Multiplexed binding assays for receptor arrays |
| JP2005522989A (ja) | 2001-10-25 | 2005-08-04 | アステックス テクノロジー リミテッド | チトクロムｐ４５０２ｃ９の結晶、その構造、およびその使用 |
| US7115377B2 (en) * | 2001-10-26 | 2006-10-03 | Atto Bioscience, Inc. | Cell-based assays for G-protein-coupled receptor-mediated activities |
| AU2003227268A1 (en) | 2002-03-28 | 2003-10-13 | Takeda Chemical Industries, Ltd. | Novel screening method |
| JP2004238384A (ja) | 2002-03-28 | 2004-08-26 | Takeda Chem Ind Ltd | 新規スクリーニング方法 |
| WO2003091282A1 (fr) | 2002-04-24 | 2003-11-06 | Banyu Pharmaceutical Co., Ltd. | Mutant a activite ordinaire du recepteur h3 de l'histamine et utilisation correspondante |
| ES2340475T3 (es) * | 2002-05-01 | 2010-06-04 | Vertex Pharmaceuticals Incorporated | Estructura cristalizada de proteina aurora-2 y sus bolsillos de union. |
| CA2498264A1 (en) * | 2002-09-09 | 2004-05-13 | Nura, Inc. | G protein coupled receptors and uses thereof |
| US20040096914A1 (en) * | 2002-11-20 | 2004-05-20 | Ye Fang | Substrates with stable surface chemistry for biological membrane arrays and methods for fabricating thereof |
| US7745161B2 (en) * | 2003-12-19 | 2010-06-29 | Palo Alto Research Center Incorporated | Amplification of enzymatic reactions for use with an enthalpy array |
| US20050287565A1 (en) * | 2004-05-12 | 2005-12-29 | Merchiers Pascal G | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| KR100575682B1 (ko) * | 2004-05-24 | 2006-05-03 | 엘지전자 주식회사 | 실외기간 균압관을 구비한 공기조화기 |
| WO2005121755A1 (en) | 2004-06-14 | 2005-12-22 | Commonwealth Scientific And Industrial Research Organisation | Cell free g-protein coupled receptor and ligand assay |
| WO2006007857A1 (en) * | 2004-07-23 | 2006-01-26 | Hvidovre Hospital | Bilf1, a constitutive active g-protein coupled receptor |
| US20060188964A1 (en) | 2004-07-28 | 2006-08-24 | Filippo Mancia | Processing for producing and crystallizing G-protein coupled receptors |
| JP2006340717A (ja) | 2005-05-11 | 2006-12-21 | Sekisui Chem Co Ltd | Ｇタンパク質共役型受容体に対する結合性評価方法及び評価用組成物、融合タンパク質、並びに、遺伝子 |
| FR2890174B1 (fr) | 2005-08-30 | 2009-04-24 | Cis Bio Internat Sa | Procede pour la mise en evidence d'un processus biologique par mesure d'un fret |
| US20070154947A1 (en) * | 2005-08-31 | 2007-07-05 | The Trustees Of Princeton University | Chemical biodiscriminator |
| WO2007097820A2 (en) * | 2005-11-18 | 2007-08-30 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
| EP2121919B1 (en) | 2007-03-22 | 2012-02-08 | Heptares Therapeutics Limited | Mutant g-protein coupled receptors and methods for selecting them |
| WO2009051769A1 (en) | 2007-10-17 | 2009-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for crystallizing g protein-coupled receptors |
| US8252899B2 (en) * | 2007-10-22 | 2012-08-28 | The Scripps Research Institute | Methods and compositions for obtaining high-resolution crystals of membrane proteins |
| GB0724051D0 (en) * | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| GB0802474D0 (en) * | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| WO2008068534A2 (en) | 2008-03-05 | 2008-06-12 | Heptares Therapeutics Limited | Crystal structure of a betal -adremergi c receptor and uses thereof |
| GB0910725D0 (en) * | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| EP3333185A1 (en) * | 2010-08-20 | 2018-06-13 | Heptares Therapeutics Limited | Mutant gpcrs |
| DK2611826T3 (en) | 2010-08-30 | 2017-01-09 | Confometrx Inc | A method and composition for the crystallization of a family-C-GPCR |
| WO2012098413A1 (en) | 2011-01-21 | 2012-07-26 | Heptares Therapeutics Limited | Mutant g-protein coupled receptor proteins and methods for producing them |
| JP2014516963A (ja) | 2011-05-13 | 2014-07-17 | レセプトス インコーポレイテッド | Ｇタンパク質共役レセプターを結晶化するための新規融合パートナー |
| DK2742066T3 (en) | 2011-08-10 | 2018-03-05 | Heptares Therapeutics Ltd | STABLE PROTEINS |
| EP2617732A1 (en) | 2012-01-19 | 2013-07-24 | Vib Vzw | Tools and methods for expression of membrane proteins |
| JP6251252B2 (ja) | 2012-06-01 | 2017-12-20 | ヘプタレス セラピューティックス リミテッド | アッセイ |
| US20150261911A1 (en) | 2014-03-13 | 2015-09-17 | Heptares Therapeutics Limited | Crystal structure |
-
2007
- 2007-12-20 GB GBGB0724860.2A patent/GB0724860D0/en not_active Ceased
-
2008
- 2008-12-19 ES ES12192130T patent/ES3006458T3/es active Active
- 2008-12-19 AU AU2008339595A patent/AU2008339595C1/en active Active
- 2008-12-19 EP EP12192130.8A patent/EP2573563B1/en active Active
- 2008-12-19 US US12/809,181 patent/US8790933B2/en active Active
- 2008-12-19 CA CA2710145A patent/CA2710145C/en active Active
- 2008-12-19 JP JP2010538902A patent/JP5763343B2/ja active Active
- 2008-12-19 EP EP08865061.9A patent/EP2235533B1/en active Active
- 2008-12-19 WO PCT/GB2008/004223 patent/WO2009081136A2/en not_active Ceased
- 2008-12-19 GB GB1000386.1A patent/GB2468006C/en active Active
-
2014
- 2014-04-17 US US14/255,939 patent/US9260505B2/en active Active
-
2015
- 2015-06-10 JP JP2015117562A patent/JP6425620B2/ja active Active
-
2016
- 2016-01-06 US US14/989,744 patent/US10126313B2/en active Active
-
2018
- 2018-10-04 US US16/151,991 patent/US20190094247A1/en not_active Abandoned
-
2020
- 2020-11-30 US US17/107,617 patent/US20210148939A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011508875A5 (enExample) | ||
| US20210148939A1 (en) | Methods for screening for binding partners of g-protein coupled receptors | |
| CN102257390B (zh) | 半乳凝素-3免疫测定法 | |
| Vidic et al. | Quantitative assessment of olfactory receptors activity in immobilized nanosomes: a novel concept for bioelectronic nose | |
| Wang et al. | Microarray based screening of peptide nano probes for HER2 positive tumor | |
| Locatelli-Hoops et al. | Surface plasmon resonance applied to G protein-coupled receptors | |
| Alves et al. | Plasmon resonance methods in GPCR signaling and other membrane events | |
| WO2013035799A1 (ja) | ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法 | |
| US20200231949A1 (en) | G proteins | |
| CN104903727B (zh) | 诊断、预后、治疗和筛选方案 | |
| Ranjbari et al. | Surface plasmon resonance biosensors for early troponin detection | |
| Murray et al. | Microarray-formatted clinical biomarker assay development using peptide aptamers to anterior gradient-2 | |
| US20040121413A1 (en) | Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions | |
| Arnold et al. | Antibody binding reports spatial heterogeneities in cell membrane organization | |
| TW201818958A (zh) | 製造和使用可溶性主要組織相容性複合體（ｍｈｃ）分子類之方法 | |
| CN104126122B (zh) | 与胰岛素受体族反应抗体结合性能调节剂之识别 | |
| US20030059827A1 (en) | Engineered protein binding domains and methods and systems for their design and use | |
| Smith et al. | Location of auxilin within a clathrin cage | |
| Kriechbaumer et al. | Quantification of ligand binding to G-protein coupled receptors on cell membranes by ellipsometry | |
| US20180003631A1 (en) | Surface plasmon resonance approach to monitor protein-ligand interactions | |
| CN114402201A (zh) | 川崎病罹患判定试剂盒和川崎病罹患判定方法 | |
| Fang et al. | with stage progression. Taken together, these data suggest that the level of EphA10 expression partly contributes to breast cancer progression. Next, we evaluated the relationship between EphA10 protein expression and clinicopathological characteristics. |